Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitomycin C in Incurable HNSCC
NCT02369458Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2015
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mitomycin c in head and neck squamous cell carcinoma (HNSCC) (2 cohorts), sponsored by Washington University School of Medicine. Primary endpoint: Tumor Response Rate at 6 months. Started Apr 2015; status: completed.
02
Drugs
mitomycin c
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02369458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02369458.